Hologic, Inc.（豪洛捷公司） - Global Leader in Women's Health Diagnostics, Imaging and Surgical Solutions

Company Profile (Updated April 2026)

Hologic, Inc. is a global medical technology company primarily focused on improving women's health and well-being through early detection and treatment. Founded in 1985 by S. David Ellenbogen and Jay A. Stein and headquartered in Marlborough, Massachusetts, USA, Hologic has established itself as a leader in diagnostics products, medical imaging systems, and surgical products dedicated to women's healthcare needs.

The company operates through a global commercial network serving customers in over 110 countries, with major operations in the United States, Europe, and Asia-Pacific. Hologic combines deep clinical expertise with advanced technology to deliver innovative solutions across breast cancer screening, molecular diagnostics, gynecological surgery, and bone health.

Corporate History & Leadership Transition

Founded: 1985 by S. David Ellenbogen and Jay A. Stein
   Headquarters: 250 Campus Drive, Marlborough, MA 01752, USA
   Former CEO (2013-2026): Steve MacMillan
   Current CEO (from April 2026): José (Joe) E. Almeida
   Company Type: Private Company (formerly Nasdaq: HOLX, 1990-2026)
   FY2025 Revenue: ~$4.1 billion
   FY2024 Revenue: $4.03 billion
   Q1 FY2026 Revenue: $1,047.8 million (+2.5% reported)
   Website: www.hologic.com

Under Steve MacMillan's leadership from December 2013 to April 2026, Hologic achieved transformative growth across revenue, profitability, and share price performance, while expanding the workforce by more than 1,500 people. MacMillan previously served as CEO of Stryker (2005-2012) and held senior executive roles at Johnson & Johnson and Pharmacia.

José (Joe) E. Almeida, the new CEO appointed in April 2026, is an accomplished MedTech leader who previously served as Chairman and CEO of Baxter International and CEO of Covidien. He brings extensive experience in global healthcare leadership to drive Hologic's next phase of growth as a private company.

Business Segment Structure

Diagnostics

Q1 FY2026 Revenue: $464.4 million (44.3% of total)
   Focus: Molecular diagnostics, cytology, perinatal testing, and blood screening
   Key Products:

- Panther Platform: Fully automated molecular diagnostics system; workhorse platform for Aptima women's health assays, infectious disease testing, and respiratory panels

- Aptima Women's Health: Market-leADINg molecular assays for HPV, chlamydia, gonorrhea, and trichomonas

- ThinPrep Pap Test: Liquid-based cytology for cervical cancer screening

- Biotheranostics (BCI): Breast Cancer Index genomic test for therapy guidance; $100 million+ revenue business growing at solid double-digit rates

- BV/CV/TV Assays: Bacterial vaginosis, candidiasis, and trichomonas testing; approximately Hologic's second largest assay generating several hundred million dollars annually

- Blood Screening: Donor screening solutions (~$20M annually)

Breast Health

Q1 FY2026 Revenue: $375.9 million (35.9% of total)
   Focus: Comprehensive portfolio of solutions for breast cancer care across radiology, breast surgery, pathology, and treatment
   Key Products:

- 3D Dimensions Mammography Systems: Market-leading digital breast tomosynthesis technology with approximately 65% of U.S. installed base market share; clinical superiority to 2D mammography

- Selenia Dimensions: Full-field digital mammography system

- Interventional Breast Solutions: Portfolio of disposable needles, biopsy devices, and tissue markers; includes BioZorb (withdrawn from market in 2024, less than $10M revenue impact)

- Endomagnetics: Acquired magnetic sentinel node and tumor localization technology

- Genius Digital Cytology: AI-powered cervical cancer screening system launched in the U.S. in Q4 2024

GYN Surgical

Q1 FY2026 Revenue: $180.8 million (17.3% of total)
   Focus: Minimally invasive solutions for abnormal uterine bleeding, uterine fibroids, and pelvic conditions
   Key Products:

- NovaSure Endometrial Ablation System: Market-leading device for treating abnormal uterine bleeding; experiencing domestic decline but growing internationally

- MyoSure Hysteroscopic Tissue Removal System: Devices for removing fibroids and polyps

- Fluent Fluid Management System: Advanced fluid management for hysteroscopic procedures

- Acessa ProVu System: Laparoscopic radiofrequency ablation for uterine fibroids; acquired through Gynesonics acquisition ($350M, October 2024), including Sonata System for transvaginal ultrasound-guided fibroid ablation

Skeletal Health

Q1 FY2026 Revenue: ~$26.7 million (2.5% of total)
   Focus: Bone densitometry and mini C-arm imaging
   Key Products:

- Horizon DXA System: Advanced bone densitometer for osteoporosis diagnosis

- Discovery DXA Systems: Bone health assessment platforms

- Fluoroscan Insight FD: Mini C-arm imaging system for orthopedic surgery (discontinued in 2025)

Financial Performance (FY2024 - Q1 FY2026)

Fiscal Year 2024 (Ended September 28, 2024)

- Total Revenue: $4.03 billion (-0.2% reported; +5.3% organic excluding COVID)

- Non-GAAP EPS: $4.08 (+3%)

- Q4 FY2024 Revenue: $987.9 million (+4.2% reported; +5.0% organic ex-COVID)

- Q4 Non-GAAP EPS: $1.01 (+13.5%)

- Capital Deployment: $808 million share repurchases (11.2M shares); $250M accelerated share repurchase program announced

Fiscal Year 2025 (Ended September 27, 2025)

- Q1 FY2025 Revenue: $1,021.8 million (+0.9%)

- Q2 FY2025 Revenue: $1,005.3 million (-1.2%)

- Q3 FY2025 Revenue: $1,023.8 million (+0.4%)

- Q4 FY2025 Revenue: $1,049.5 million (exceeded guidance)

- Full Year FY2025 Revenue: ~$4.1 billion (estimated)

- Q4 Non-GAAP EPS: $1.13

- Full Year Non-GAAP EPS: ~$4.23-$4.26 range

Q1 Fiscal Year 2026 (Ended December 27, 2025)

- Revenue: $1,047.8 million (+2.5% reported; +2.1% constant currency)

- GAAP Diluted EPS: $0.79 (-9.2%)

- Non-GAAP Diluted EPS: $1.04 (+1.0%)

- GAAP Gross Margin: 56.0%

- Non-GAAP Gross Margin: 60.1%

- Adjusted EBITDA: $330.4 million

- Operating Cash Flow: $229.9 million (+21.4%)

- Cash Position: $2.17 billion

- Net Leverage Ratio: 0.3x (extremely healthy balance sheet)

- Tariff Impact: $15.3 million in Q1 FY2026

- Geographic Revenue Split: U.S. 73.8%, Europe 15.4%, Asia-Pacific 5.4%, Rest of World 5.4%

- Instrument Book-to-Bill: At or above 1 for eighth consecutive quarter

Strategic Growth Drivers

International Expansion: International revenue has grown nearly 50% since 2019, representing a significant growth opportunity. Management expects international growth to outpace domestic growth, with particular focus on Europe and Asia-Pacific markets.

Genius Digital Cytology: AI-powered cervical cancer screening system launched in the U.S. in Q4 2024, representing a major market-creating innovation that leverages Hologic's established ThinPrep installed base.

Breast Health Replacement Cycle: New gantry technology expected to drive reacceleration in fiscal 2026-2028, following normalization of chip shortage impacts and replacement of existing installed base.

Biotheranostics Growth: BCI (Breast Cancer Index) genomic test continues to deliver solid double-digit growth with low market penetration, suggesting multi-year expansion runway.

Gynesonics Integration: $350M acquisition of Sonata System for minimally invasive fibroid treatment expands Hologic's GYN Surgical portfolio and creates cross-selling opportunities with existing NovaSure/MyoSure customer base.

Recent Strategic Developments (2024-2026)

Major Acquisition - Going Private (April 2026):

- Blackstone and TPG completed $18.3B acquisition, taking Hologic private; ADIA and GIC participated as minority investors

- Steve MacMillan retired; José (Joe) E. Almeida appointed new CEO

- CVR structure incentivizes Breast Health revenue growth in FY2026 and FY2027

Product Innovation:

- Genius Digital Cytology: AI-powered cervical cancer screening launched Q4 2024

- Panther Fusion: Expanded molecular testing menu on flagship platform

- 4-Plex Respiratory Assay: Transitioned COVID testing to multiplex respiratory panel

Strategic M&A:

- Gynesonics ($350M, October 2024): Added Sonata System for transvaginal ultrasound-guided fibroid ablation

- Endomagnetics (2024): Magnetic sentinel node and tumor localization technology

Operational Excellence:

- Manufacturing facility consolidation in Breast Health to drive long-term margin expansion

- Supply chain normalization following chip shortage disruptions

2026 Outlook & Strategic Vision (As Private Company)

Leadership Transition: Under new CEO Joe Almeida, Hologic is positioned to leverage Blackstone and TPG's capital and operational expertise to accelerate innovation and global expansion while maintaining its focus on women's health leadership.

Breast Health Reacceleration: New gantry launch expected to drive replacement cycle and revenue growth in fiscal 2026-2028, supported by AI-enhanced imaging capabilities and service revenue expansion.

Diagnostics Growth: Continued double-digit growth in Biotheranostics and BV/CV/TV assays, plus Genius Digital Cytology rollout, expected to drive molecular diagnostics segment performance.

International Expansion: Targeting faster growth outside the U.S. through deeper market penetration, geographic expansion, and leveraging strong local currencies.

Surgical Portfolio Expansion: Integration of Gynesonics/Sonata technology with existing NovaSure/MyoSure platforms to create comprehensive minimally invasive women's health surgical solutions.

CVR Milestones: Management focused on achieving Breast Health revenue targets in fiscal 2026 and 2027 to maximize CVR payouts for former shareholders, incentivizing strong execution in the core mammography business.

Contact Information

Global Headquarters

Company: Hologic, Inc.
   Address: 250 Campus Drive, Marlborough, MA 01752, USA
   Phone: +1 (781) 999-7300
   Website: www.hologic.com
   Investor Relations (Historical): investors.hologic.com

Key Personnel

CEO (from April 2026): José (Joe) E. Almeida
   Former CEO (2013-2026): Steve MacMillan
   CFO: Karleen Oberton

Keywords: Hologic Inc,豪洛捷,women's health,diagnostics,breast health,GYN surgical,skeletal health,3D mammography,Panther platform,NovaSure,MyoSure,Fluent,Acessa,Sonata,Genius Digital Cytology,Biotheranostics,BCI,BV/CV/TV,ThinPrep,Aptima,Horizon DXA,Blackstone,TPG,go-private,18.3 billion,Steve MacMillan,Joe Almeida,Marlborough,Massachusetts,Nasdaq HOLX,ADIA,GIC,CVR,Q1 FY2026,464.4 million,375.9 million,180.8 million,26.7 million,1.047 billion,60.1% gross margin,330.4 million EBITDA,2.17 billion cash,0.3x leverage